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ABSTRACT
Objective To systematically review interventional studies
of the effects of alcohol consumption on 21 biological
markers associated with risk of coronary heart disease in
adults without known cardiovascular disease.
Design Systematic review and meta-analysis.
Data sources Medline (1950 to October 2009) and
Embase (1980 to October 2009) without limits.
Study selection Two reviewers independently selected
studies that examined adults without known
cardiovascular disease and that compared fasting levels
of specific biological markers associated with coronary
heartdiseaseafteralcoholusewiththoseafteraperiodof
noalcoholuse(controls).4690articleswerescreened for
eligibility, the full texts of 124 studies reviewed, and 63
relevant articles selected.
Results Of 63 eligible studies, 44 on 13 biomarkers were
meta-analysed in fixed or random effects models. Quality
was assessed by sensitivity analysis of studies grouped
by design. Analyses were stratified by type of beverage
(wine,beer,spirits).Alcoholsignificantlyincreasedlevels
of high density lipoprotein cholesterol (pooled mean
difference 0.094 mmol/L, 95% confidence interval 0.064
to 0.123), apolipoprotein A1 (0.101 g/L, 0.073 to 0.129),
and adiponectin (0.56 mg/L, 0.39 to 0.72). Alcohol
showed a dose-response relation with high density
lipoprotein cholesterol (test for trend P=0.013). Alcohol
decreased fibrinogen levels (−0.20 g/L, −0.29 to −0.11)
but did not affect triglyceride levels. Results were similar
for crossover and before and after studies, and across
beverage types.
Conclusions Favourable changes in several
cardiovascular biomarkers (higher levels of high density
lipoprotein cholesterol and adiponectin and lower levels
of fibrinogen) provide indirect pathophysiological
support fora protective effectof moderatealcoholuse on
coronary heart disease.
INTRODUCTION
Moderate alcohol consumption (up to one drink a day
for women and up to two for men)has been associated
with a decreased risk for certain cardiovascular
diseases,particularlycoronaryheartdisease,inseveral
studies of diverse populations.
12Most of these studies,
however, used an observational design, raising con-
cerns about potential confounding.
Feeding studies (where alcohol is experimentally
administered) free of concerns about confounding
may help to elucidate the mechanisms by which alco-
holaffectscardiovasculardisease.In1999,asystematic
reviewofexperimentalstudiesofalcoholconsumption
and changes in lipid levels and haemostatic factors
asserted that the protective association of alcohol on
certain cardiovasculardiseases seemedto be mediated
by some of these effects.
3 Since that systematic review
waspublishedthe breadthofresearchonthistopic has
expanded substantially. Atherosclerosis, the underly-
ing cause of coronary heart disease and ischaemic
stroke, is increasingly understood to be a chronic, low
grade inflammatory disease of the arterial wall.
4
Increased levels of inflammatory markers have been
associated with risk of cardiovascular disease.
56 New
studies have examined not only the effect of alcohol
on lipid levels and haemostatic factors but also on
other measures of inflammation and endothelial cell
function as well as levels of adipocyte hormones.
Furthermore, in addition to haemostatic factors,
increased levels of other molecules, such as cellular
adhesion molecules and adipocyte hormones, are
believed to contribute to the development of the sys-
temic inflammatory response associated with
increased risk of cardiovascular disease.
478
A synthesis of the evidence from experimental
research in this area may inform clinicians trying to
interpret the plausibility of the protective effects of
alcohol on certain aspects of cardiovascular disease
(coronary heart disease) from observational studies.
We therefore systematically reviewed the effect of
experimentally manipulated alcohol consumption
(alcohol use versus a period of no alcohol use) on the
circulating concentrations of selected cellular and
molecular biological markers of atherothrombotic
conditions associated with increased coronary heart
disease risk in adults without pre-existing
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tary, indirect mechanistic evidence to that obtained
from the expanding epidemiological research on the
apparent protectiveeffect of alcohol on certain aspects
of cardiovascular disease.
910
METHODS
The systematic review was carried out using a prede-
termined protocol and in accordance with published
guidelinesforreportingofsystematicreviewsofrando-
mised controlled trials (PRISMA).
Data sources and searches
We searched for alcohol intervention studies in adults
without pre-existing cardiovascular disease in whom
circulating levels of specific biomarkers were mea-
suredafteraspecifiedamountofalcoholhadbeencon-
sumed within a defined timeframe compared with a
period of no alcohol use. We searched Medline (1950
to October 2009) and Embase (1980 to October 2009)
without language restrictions for potentially relevant
articles.
Weusedastrategyrecommendedforsearchingelec-
tronicdatabasesforcontrolledinterventionalstudies.
11
Our search focused on the exposure of interest, rele-
vant outcomes, and study designs. The exposure of
interest was alcohol consumption. The relevant out-
comes were circulating atherothrombotic biological
markers associated with coronary heart disease.
These included lipids (triglycerides, total cholesterol,
high density lipoprotein cholesterol, low density lipo-
proteincholesterol,Lp(a)lipoprotein,andapolipopro-
tein A1), inflammatory markers (C reactive protein,
leucocytes, interleukin 6, tumour necrosis factor α,
and haemostatic factors plasminogen activator inhibi-
tor 1, von Willebrand factor, tissue plasminogen acti-
vator, fibrinogen, and e-selectin), endothelial cell
function markers (intracellular adhesion molecule 1
and vascular cell adhesion molecule), and adipocyte
hormones (leptin and adiponectin). Our study designs
of interest were experimental studies involving an
intentional alcohol intervention to modify levels of
biological markers with a no alcohol control. We
included randomised controlled trials with two arms,
Articles from electronic literature search (n=4692)
Articles selected for full text review (n=126)
Articles included in qualitative synthesis (n=63)
Included in meta-analyses (n=44)
Excluded based on title and abstract screening (existing cardiovascular disease; alcohol not intervention; alcohol
risk factor used in risk adjustment; intervention was heavy drinking; control period was not abstention; outcome was
not biomarkers of interest; outcome was other than plasma levels of biomarkers; or observational study) (n=4566)
High density
lipoprotein
cholesterol (n=44)
Low density
lipoprotein
cholesterol (n=28)
Cholesterol (n=32)
Plasminogen (n=1)
Triglycerides
(n=39)
Apolipoprotein A1
(n=22)
Lp(a) lipoprotein
(n=5)
Plasminogen
activator
inhibitor 1 (n=3)
Intracellular
adhesion
molecule 1 (n=3)
Vascular cell
adhesion
molecule (n=2)
Tissue
plasminogen
activator (n=4)
Leucocytes (n=1)
Interleukin 6 (n=4)
C reactive protein
(n=8)
Fibrinogen (n=8)
Adiponectin (n=7)
Leptin (n=2)
e-selectin (n=2)
Tumour necrosis
factor α (n=7)
von Willebrand
factor (n=2)
Thromboxane
(n=1)
Excluded (n=63):
  Alcohol intervention not controlled (n=12)
  Inappropriate outcome (n=7)
  Duplicate data (n=6)
  Acute alcohol use (n=35)
  Underlying cardiovascular disease (n=3)
Endothelial
factors (n=3)
Adipocyte
hormones (n=8)
Haemostatic
factors (n=14)
Inflammatory
markers (n=13)
Lipid biomarkers
(n=47)
Fig 1 | Flow of studies through review
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of biomarkers associated with cardiovascular disease
Source Participants Study design
Characteristics of
participants
Alcoholintervention
and diet Biomarkers sampled
Included in meta-
analysis
Reasons
for exclusion from
meta-analysis
Baer 2002
20 51; all women;
mean age 60
Random
crossover
Postmenopausal; no
hyperlipidaemia, no
diabetes, and no
peripheral vascular
disease
8 weeks of 15 g/day
and 30 g/day 95%
ethanol(1or 2 drinks
aday);controlleddiet
Triglycerides, total cholesterol,
high and low density
lipoprotein cholesterol, and
apolipoprotein A1
No Data reported as least
mean squares
Bantle 2008
21 17; 7 men; age
≥40
Random
crossover
Type 2 diabetes, no
hypertension, no
heart failure, and not
receiving insulin*
1 month (12 g/day
women, 24 g/day
men) red or white
wine (1-2 drinks a
day); usual diet
Triglycerides, total cholesterol,
low and high density
lipoprotein cholesterol, C
reactive protein, and
plasminogen
Yes —
Belfrage 1973
22 8; all men; age
22-26
Before and after Healthy (includes
some smokers)
5 weeks of 63 g/day
beer (5 drinks a day);
usual diet
Triglycerides, total cholesterol,
and low and high density
lipoprotein cholesterol
No Error measurements
not provided
Belfrage 1977
23 9; all men; age
22-29
Before and after Healthy (includes
some smokers)
4 weeks of 75 g/day
beer or ethanol (6
drinks a day)†
Triglycerides and high density
lipoprotein cholesterol
No Dataprovidedingraph
format only
Bertiere 1986
24 10; all men; age
18-21
Before and after Healthy (includes
some smokers)
4 weeks of 30 g/day
redwine(2.5drinksa
day); usual diet
Cholesterol, triglycerides, low
and high density lipoprotein
cholesterol, and
apolipoprotein A1
Yes except for
apolipoprotein A1
Data reported as
density fraction
Beulens 2008
27 20; all men; age
18-25
Random
crossover
All healthy, lean, or
overweight, non-
smokers
3 weeks of 40 g/day
beer (3 drinks a day);
controlled diet
Cholesterol, triglycerides, low
and high density lipoprotein
cholesterol, and C reactive
protein
Yes —
Beulens 2008
28 19; all men; age
18-25
Random
crossover
Healthy, lean, or
overweight
3 weeks of 40 g/day
beer (3 drinks a day);
usual diet
Adiponectin Yes —
Beulens 2007
26 19; all men; age
18-40
Random
crossover
Healthy, lean or
overweight
4 weeks of 32 g/day
whisky (2.5 drinks a
day); partially
controlled diet
Adiponectin Yes —
Beulens 2006
25 34; all men; age
35-70
Random
crossover
Abdominal obesity,
no cardiovascular
disease,nodiabetes,
non-smokers
4 weeks of 40 g/day
red wine (3 drinks a
day); usual diet
High density lipoprotein
cholesterol and adiponectin
Yes, except for high
density lipoprotein
cholesterol
Error measurements
not provided
Burr 1986
29 100; 48 men
(age 20-56). 52
women (age 19-
60)
Random
crossover
No diabetes and not
taking
antihypertensive
drugs*
4 weeks (19 g/day
men, 17.8 g/day
women)beer,wine,or
spirits (1.5 drinks a
day)†
Triglycerides, total cholesterol,
low and high density
lipoprotein cholesterol, and
fibrinogen
Yes —
Cartron 2003
30 18; all men; age
20-45
Random
crossover
Normal cholesterol
and triglyceride
levels, no drugs or
vitamins, non-
smokers
3 weeks of 26 g/day
(250 ml/day) white
wine, champagne, or
red wine (2 drinks a
day); controlled diet
Total cholesterol, triglycerides,
and apolipoprotein A1
Yes —
Clevidence 1995
31 34; all women;
age 21-40
Random
crossover
Premenopausal
women,healthy,non-
smokers
3monthsof30g/day
grain alcohol (2.5
drinks a day);
controlled diet
Triglycerides, total cholesterol,
low and high density
lipoprotein cholesterol,
apolipoprotein A1, and Lp(a)
lipoprotein
Yes —
Contaldo 1989
32 8; all men; age
30-47
Crossover Healthy, non-smoker
or light smoker
2 weeks of 75 g/day
(750 ml wine) (6
drinks/day);
isocaloric diet
Triglycerides, total cholesterol,
low and high density
lipoprotein cholesterol, and
apolipoprotein A1
Yes —
Couzigou 1984
33 7; all men; age
28-31;meanage
29.6
Before and after Healthy, no drugs,
usualsmokinghabits
1week23g/day,then
4weeks31g/dayred
wine(1.5,2.5drinksa
day); usual diet
Low and high density
lipoprotein cholesterol and
apolipoprotein A1
Yes —
Crouse 1984
34 12; all men; age
22-62
Before and after No liver dysfunction,
no metabolic
disorders, no
diabetes; 3 had
hyperglycaemia, 2
atherosclerosis *
4weeks90g/day‡(7
drinks a day);
controlled diet
Triglycerides, total cholesterol,
and low and high density
lipoprotein cholesterol
Yes —
Davies 2002
35 51; all women;
mean age 59.5
Random
crossover
Post-menopausal,
healthy
8 weeks of 15 g/day
or30g/day‡(1or2.5
drinks a day);
controlled diet
Triglycerides Yes —
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for exclusion from
meta-analysis
De Oliveira e Silva
2000
36
14; 9 men; age
21-70;meanage
53.3
Crossover Without significant
disease, non-
smokers
2 weeks of 1mL/kg/
day vodka (1.5-2
drinks a day);
controlled diet
Total cholesterol, triglycerides,
and low and high density
lipoprotein cholesterol
Yes —
Djurovic 2007
37 87; 30 men; age
35-70
Random
crossover
Healthy, non-
smokers
3 weeks of 16 g/day
(150 mL) red wine (1
drink a day)†
C reactive protein, tumour
necrosis factor α,i n t e r l e u k i n6 ,
intracellular adhesion
molecule 1, vascular cellular
adhesion molecule, and leptin
Yes, except for C
reactive protein,
tumour necrosis
factor α, intracellular
adhesionmolecule1,
vascular cellular
adhesion molecule,
and leptin
Creactiveprotein:data
reportedascorrelation
with leptin; tumour
necrosis factor α:n o n -
detectable change
reported; leptin,
intracellular adhesion
molecule 1, vascular
cellular adhesion
molecule: only one
study reportingusable
data
Estruch 2004
38 40; all men; age
30-50;meanage
37.6
Random
crossover
Excludes those with
hypertension,
diabetes, high low
density lipoprotein
cholesterol, low high
density lipoprotein
cholesterol, coronary
heart disease,
cerebrovascular
disease, peripheral
vascular disease;
non-smokers
28 days of 33 g/day
(320 mL) red wine or
(100 mL) gin (2.5
drinks a day);
isocaloric diet
C reactive protein, fibrinogen,
e-selectin, tumour necrosis
factor α, intracellular adhesion
molecule 1, and vascular
cellular adhesion molecule
Yes except for e-
selectin intracellular
adhesionmolecule1,
and vascular cellular
adhesion molecule
e-selectin: only study
reporting suitable
data; intracellular
adhesion molecule 1,
vascular cellular
adhesion molecule:
reports on other
cellular adhesion
molecules
Fraser 1983
39 10; all men Crossover Generally healthy 3 weeks of 10-74 g/
daybeerorwhisky(1-
5 drinks a day);
controlled diet
High density lipoprotein
cholesterolandapolipoprotein
A1
Yes —
Frimpong 1989
40 8; all men; age
21-35
Before and after Healthy, with normal
lipid levels, non-
smokers
6 weeks of 40 g/day
beer (3 drinks a day);
controlled diet
Triglycerides, total cholesterol,
and low and high density
lipoprotein cholesterol
Yes —
Glueck 1980
41 6;allmen;18-19 Before and after Healthy, normal lipid
profile
1week of 35 g/day,
1w e e k5 3g / d a y
vodka (2 then 3.5
drinks a day);
controlled diet
Triglycerides, total cholesterol,
and high and low density
lipoprotein cholesterol
Yes —
Goldberg 1996
42 24; all men; age
26-45
Crossover Healthy 4 weeks of 40 g/day
redwineorwhitewine
(3drinksaday);usual
diet
Triglycerides, total cholesterol,
high density lipoprotein
cholesterol, and
apolipoprotein A1
Yes —
Gottrand 1999
43 5;allmen;mean
age 22.8
Random
crossover
Healthy, non-
smokers, no drugs
4 weeks of 50 g/day
red wine (4 drinks a
day); controlled diet
Triglycerides, total cholesterol,
high density lipoprotein
cholesterol,apolipoproteinA1,
and Lp(a) lipoprotein
Yes —
Hagiage 1992
44 14; all men;
mean age 28
Before and after Healthy, light or non-
smokers, without
history of chronic
illness;7werenormal
weight, 7 were obese
2 weeks of 30 g/day
redwine(2.5drinksa
day); usual diet
Triglycerides, total cholesterol,
high and low density
lipoprotein cholesterol,
apolipoprotein A1, and Lp(a)
lipoprotein
Yes —
Hansen 2005
45 19; 9 men; age
38-75;meanage
50
Random
crossover
No lipid lowering
drugs or
antihypertensives,
includes some
smokers
4 weeks (38.3 g/day
men, 25.5 g/day
women)redwine(1.5
or 2.5 drinks a day);
controlled diet
Total cholesterol, high and low
densitylipoproteincholesterol,
and fibrinogen
Yes —
Hartung 1983
46 44; all men; age
27-59
Before and after 16 marathoners, 15
joggers and 13
inactive; all healthy*
3weeksof37.5g/day
beer (3 drinks a day);
usual diet
Triglycerides, total cholesterol,
and high and low density
lipoprotein cholesterol
Yes —
Hartung 1986
47 32; all women;
age 30-49
Before and after Premenopausal, half
were habitual
runners,halfinactive;
some smokers in
inactive group
3 weeks of 35 g/day
wine(3drinksa day);
usual diet
Triglycerides, total cholesterol,
high and low density
lipoprotein cholesterol, and
apolipoprotein A1
Yes —
Hartung 1990
48 49; all men; age
30-54
Before and after 26 habitual runners,
23 inactive; all
healthy; some
smokers in inactive
group
3weeksof12.5g/day
or 37.5 g/day beer (1
or 3 drinks a day)†
High density lipoprotein
cholesterolandapolipoprotein
A1
Yes —
Imhof 2009
49 Adiponectin No
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participants
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Included in meta-
analysis
Reasons
for exclusion from
meta-analysis
72; 36 men; age
22-56
Random
crossover
Healthy, non-
smokers
3 weeks (30 g/day
men, 20 g/day
women)ofbeer,wine,
or ethanol (2-2.5
drinks a day)
Data presented as
percentage change
Jensen 2006
50 80; 28 men; age
35-70
Random
crossover
Healthy, non-
smokers
3weeks15g/dayred
wine (1 drink a day)†
Fibrinogen Yes —
Joosten 2008
51 36; all women;
mean age 56.5
Crossover Postmenopausal,
healthy*
6 weeks of 20 g/day
whitewine(1.5drinks
a day); usual diet
Triglycerides, total cholesterol,
high and low density
lipoprotein cholesterol, and
adiponectin
Yes —
Karlsen 2007
52 49; 15 men; age
35-70
Random
prospective two
arm control
Healthy, non-
smokers, no
cardiovascular
disease,nodiabetes,
no liver disease, no
lipid lowering drugs,
no aspirin
3 weeks of 15 g/day
red wine (1 drink a
day)†
Interleukin 6 and tumour
necrosis factor α
No Data presented as
median difference
Malmendier 1985
53 9; all men; age
23-39
Before and after Healthy, no drugs, no
history of
cardiovascular
disease,nodiabetes,
no
hyperlipoproteinae-
mia;7normalweight,
2o b e s e
2 weeks of 60 g/day
(normal weight) or
70 g/day (obese) gin
orvodka(5-6drinksa
day); isocaloric diet
Triglycerides, total cholesterol,
high and low density
lipoprotein cholesterol, and
apolipoprotein A1
Yes —
McConnell 1997
54 20; 11 men; age
23-51
Before and after Healthy, non-
smokers, no
hyperlipidaemia, no
coronary disease, no
vascular disease, no
hypertension, no
diabetes
6weeksof16.5g/day
beer (1.5 drinks a
day); usual diet
Triglycerides, high and low
densitylipoproteincholesterol,
apolipoprotein A1, Lp(a)
lipoprotein, tissue
plasminogen activator,
plasminogenactivatorinhibitor
1, and von Willebrand factor
Yes except for Lp(a)
lipoprotein and von
Willebrand factor
Lp(a) lipoprotein:
incongruent units of
analysis; von
Willebrandfactor:data
presented as
percentage normal
Mezzano 2003
56 42; all men;
mean age
22 years
Before and after Healthy, non-
smokers
30daysof23.2g/day
red wine (2 drinks a
day); specialised
diets
von Willebrand factor No Too few studies for
meta-analysis
Mezzano 2001
55 42; all men;
mean age 22
Before and after Healthy, non-
smokers
30daysof23.2g/day
red wine (2 drinks a
day); specialised
diets
C reactive protein, fibrinogen,
tissue plasminogen activator,
and plasminogen activator
inhibitor 1
Yes —
Naissides 2006
57 19; all women;
age50-70(mean
age 58.4)
Random
prospective two
arm control
Postmenopausal,
moderately
hypercholesterolae-
mic, excludes obese,
physically active,
smokers,poordiet,or
those receiving lipid
lowering drugs
6 weeks of 40 g/day
red wine (3 drinks a
day); controlled diet
Triglycerides, total cholesterol,
and high and low density
lipoprotein cholesterol
No Data in graph format
Nishiwaki 1994
58 25; all men;
mean age 31.4
Before and after Healthy, no diabetes 4 weeks of 30-49 g/
day (0.5 g/kg for 3
hours after dinner)
alcohol‡(2-4drinksa
day); controlled diet
Triglycerides, total cholesterol,
high density lipoprotein
cholesterol, and
apolipoprotein A1
No Data in graph format
Pace-Asciak 1996
59 24; all men; age
26-45
Crossover Healthy 4 weeks of 40 g/day
redorwhitewine(2.5
drinks a day); usual
diet
Thromboxane No Only study reporting
on this biomarker
Pikaar 1987
60 12; all men; age
21-29
Random
crossover
Healthy, non-
smokers
5 weeks of 25 g/day
or50g/day wine(2-4
drinks a day); usual
diet
Triglycerides, total cholesterol,
high density lipoprotein
cholesterol, plasminogen, and
tissue plasminogen activator
No Error measurements
not provided
Retterstol 2005
61 87; 30 men; age
35-70
Random
crossover
Healthy, non-
smokers
3 weeks of 15 g/day
red wine (1 drink a
day)†
Triglycerides, total cholesterol,
high density lipoprotein
cholesterol, C reactive protein,
and fibrinogen
Yes —
Romeo 2007
63 57; 30 men; age
25-50
Before and after “Medically healthy,”
nochronicconditions
involving immune
system
1 month (22 g/day
men, 11 g/day
women) beer (1-2
drinks a day); usual
diet
Leucocytes No Only study reporting
on this biomarker
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Romeo 2007
62 57; 30 men; age
25-50
Before and after “Medically healthy,”
nochronicconditions
involving immune
system
1 month (22 g/day
men, 11 g/day
women) of beer (1-2
drinks a day); usual
diet
Interleukin 6, tumour necrosis
factor α
Yes —
Roth 2003
64 53; all women;
age ≥49; mean
age 59.7
Random
crossover
Healthy, non-
smokers,
postmenopausal
8 weeks of 15 g/day
or 30 g/day alcohol‡
(1or2.5drinksaday);
controlled diet
Leptin No Reported as
percentage change
and geometric mean
Schneider 1985
65 6;4men;age27-
33
Before and after Healthy 4 weeks of 70-80 g/
day white wine (5-6
drinks a day);
controlled diet
Triglycerides, total cholesterol,
and high and low density
lipoprotein cholesterol
No Data in graph format
Senault 2000
66 56; all men; age
18-35
Random
crossover
Healthy, no drugs 2 weeks of 30 g/day
red wine or
hydroalcohol (2.5
drinks a day); usual
diet
Trigylcerides, total cholesterol,
high and low density
lipoprotein cholesterol,
apolipoprotein A1, and Lp(a)
lipoprotein
Yes —
Sharpe 1995
67 20; 11 men; age
25-60;meanage
37.2
Before and after Healthy 10 days of 21 g/day
redorwhitewine(1.5
drinks a day); usual
diet
Total cholesterol, triglycerides,
high and low density
lipoprotein cholesterol,
apolipoprotein A1, and Lp(a)
lipoprotein
Not Lp(a) lipoprotein Error measurements
not provided
Sierksma 2004
72 23; all men; age
45-65;meanage
52
Random
crossover
Apparently healthy
non-smokers
17 days of 40 g/day
whisky (3.5 drinks a
day); controlled diet
Triglycerides, high density
lipoproteincholesterol,tumour
necrosis factor α,a n d
adiponectin
No Error measurements
not provided
Sierksma 2004
71 18; all women;
age49-65;mean
age 57
Random
crossover
Postmenopausal,
non-smokers,
healthy
3 weeks of 24 g/day
whitewine(2drinksa
day); usual diet
Triglycerides, high density
lipoprotein cholesterol, total
cholesterol, and
apolipoprotein A1
Yes —
Sierksma 2002
69 19; 10 men (age
45-64),9women
(age 49-62)
Random
crossover
Women
postmenopausal,
healthy, no
prescribed drugs
3 weeks of (men)
40 g/day and
(women) 30 g/day (3
and 2.5 drinks a day,
respectively) beer;
controlled diet
High density lipoprotein
cholesterolandapolipoprotein
A1
No Data reported as
percentage change
Sierksma 2002
70 19; 10 men (age
45-64),9women
(age 49-62)
Random
crossover
Women
postmenopausal,
healthy, no
prescribed drugs
3 weeks of (men)
40 g/day and
(women) 30 g/day (3
and 2.5 drinks a day,
respectively) beer;
usual diet
Triglycerides, high density
lipoprotein cholesterol, C
reactiveprotein,andfibrinogen
NotC reactiveprotein Data presented as
median change
Sierksma 2001
68 19; 10 men (age
45-64),9women
(age 49-62)
crossover Healthy, non-
smokers;
postmenopausal
women
3 weeks of (men)
40 g/day and
(women) 30 g/day (3
and 2.5 drinks a day,
respectively) beer;
controlled diet
Fibrinogen No Data in graph format
Suzukawa 1994
73 12; all men;
mean age 31.4
Random
prospective two
arm control
Healthy, normal
anthropometrics
4 weeks of 0.5 g/kg/
daybrandy(2drinksa
day); usual diet
Triglycerides, total cholesterol,
and high and low density
lipoprotein cholesterol
Yes —
Thornton 1983
74 12; 3 men; age
39-57;meanage
47
Before and after Healthy,
normolipidaemic,
non-smokers
6 weeks 39 g/day
wine (3.5 drinks a
day); usual diet
Triglycerides, total cholesterol,
and high and low density
lipoprotein cholesterol
Yes —
Tsang 2005
75 12;unclearNoof
men; age 23-50
Random
prospective two
arm control
Healthy, non-
smokers
2weeksof39.7g/day
redwine(3.5drinksa
day); controlled diet
Triglycerides and high and low
density lipoprotein cholesterol
Yes —
Valimaki 1991
77 10; all men; age
27-45;meanage
36
Before and after Healthy 3 weeks of 60 g/day
wine, whisky, or
vodka (5 drinks a
day); usual diet
Triglycerides, total cholesterol,
high density lipoprotein
cholesterol, and
apolipoprotein A1
Yes —
Valimaki 1988
76 10; all men; age
30-43
Before and after Healthy 3 weeks of 30 g/day
or 60 g/day wine,
whisky, or vodka (2.5
or 5 drinks a day);
usual diet
Triglycerides, total cholesterol,
high density lipoprotein
cholesterol, and
apolipoprotein A1
Not apolipoprotein
A1
Error measurements
not provided
Van der Gaag 2001
79 11; all men; age
45-60
Random
crossover
Non-smokers,
healthy
3 weeks of 40 g/day
red wine, beer, and
gin(3.5drinksaday);
controlled diet
Triglycerides, total cholesterol,
high and low density
lipoprotein cholesterol, and
apolipoprotein A1
Yes —
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the Boolean operator “and” in varying combinations
we then combined the three comprehensive search
themes. See web extra appendix 1 for the complete
Medline search strategy.
In addition to searching the electronic databases we
consultedthebibliographyoftheonlypre-existingsys-
tematic review on this subject.
3 One of the authors
(KJM) served as our content expert and provided us
with input on captured literature and direction on per-
tinent studies in the grey literature.
Study selection
Relevant articles were selected using a two phase pro-
cess. Two researchers (SEB and PER) independently
reviewed all identified abstracts for eligibility. All
abstracts reporting on the effect of alcohol consump-
tion and relevant biomarkers in participants without
pre-existing cardiovascular disease were selected for
full text review. This initial stage was intentionally lib-
eral; we discarded only abstracts that clearly did not
meet the aforementioned criteria. The inter-rater
agreement for this stage was high (κ=0.80, 95% confi-
dence interval 0.65 to 0.94). Disagreements were
resolved by consensus. Secondly, full text articles
assessed by one reviewer (SEB) were verified by a sec-
ond reviewer (PER) to determine if the study met the
specified intervention, study population, and design
criteria. Specifically, we included studies if they evalu-
ated the circulating blood levels of the specified bio-
markers during a period of intentional, prescribed
alcohol feeding versus a period of no alcohol use. We
excluded studies if participants had pre-existing
cardiovascular disease or continued to drink “usual
alcohol” in addition to the amounts of intervention
alcohol. Both published and unpublished studies
were eligible for inclusion.
Data extraction and quality assessment
From relevant studies we extracted information on
sample size, population demographics (age, number
of men and women, and mean age or age range, or
both), inclusion and exclusion criteria (pre-existing
healthconditions,smokingstatus,drugs),studydesign
(crossover, randomised crossover, randomised two
arm, and before and after), characteristics of the alco-
hol intervention (amount, frequency, type, duration),
use of a concomitant diet intervention, biomarkers
sampled, and the mean concentration and error mea-
surements (standard deviation, standard error, or con-
fidence intervals) of specific biomarkers sampled after
the alcohol intervention and after no alcohol use.
When available we extracted information on amount
ofalcoholconsumed,usinggramsofalcoholperdayas
the common unit of measure. When a study did not
specifically report the grams of alcohol per unit, we
used12.5galcoholperdrinkforanalysis.
212Forexam-
ple,ifastudyindicatedthattheinterventionwas30gof
alcohol a day, we estimated this as 30 g alcohol a day
divided by 12.5 g alcohol a drink equals about 2.5
drinks a day. We standardised portions as a 12 oz
(355 mL) bottle or can of beer, a 5 oz (148 mL) glass
of wine, and 1.5 oz (44 mL) of 80 proof (40% alcohol)
distilled spirits.
1 We categorised the volume of alcohol
intake as <2.5 g/day (<0.5 drink), 2.5-14.9 g/day
(about0.5-1drink),15-29.9g/day(about1-2.5drinks),
30-60 g/day (about 2.5-5 drinks), and >60 g/day (≥5
drinks).
We assessed study quality using a previously out-
linedcomponentapproach.
13Studydesignwasconsid-
ered the most important measure of quality, with
randomised studies (crossover and prospective two
armcontrolledstudies)judgedtohaveahigherquality
thanbeforeandafterstudies.Wecarriedoutsensitivity
analysesbasedonstudydesigntoevaluatetheeffectof
this aspect of study quality.
13 We also reported several
Source Participants Study design
Characteristics of
participants
Alcoholintervention
and diet Biomarkers sampled
Included in meta-
analysis
Reasons
for exclusion from
meta-analysis
Van der Gaag 1999
78 11; all men; age
44-59;meanage
51.7
Random
crossover
Healthy, non-
smokers
3 weeks of 40 g/day
red wine, beer, or
spirits (3.5 drinks a
day); controlled diet
High density lipoprotein
cholesterolandapolipoprotein
A1
No Data in graph format
Van Golde 2002
80 6;allmen;mean
age 34
Before and after Healthy, non-
smokers,normalliver
function and lipid
profile
2weeksof37.5g/day
wine(3drinksaday)†
Tissue plasminogen activator
and plasminogen activator
inhibitor 1
Yes —
Vazquez-Agell 2007
81 20; all men; age
25-50
Random
crossover
Non-smokers,normal
lipids, no
hypertension, no
diabetes, no
cardiovascular
disease, no
peripheral vascular
disease
28 days of 30 g/day
gin orwhite wine(2.5
drinks a day)†
C reactive protein, interleukin
6, e-selectin, adiponectin,
tumour necrosis factor α,a n d
intracellular adhesion
molecule 1
No Data presented as
percentage change
Watzl 2004
82 24; all men;
mean age 30.6
Random
crossover
Healthy, non-
smokers
2 weeks of 53 g/day
redwineorethanol(4
drinks a day); usual
diet
Tumour necrosis factor α Yes —
*Smoking status not specified.
†Diet not specified.
‡Type of alcohol not specified.
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domisation, assessment of compliance with alcohol
consumption or abstinence, losses owing to attrition,
and relevant confounders, such as smoking, diabetes,
overweight or obesity or dietary controls. We did not
assess blinding of participants to the intervention
because it was uncertain if blinding alcohol use was
effective. We report these study characteristics based
on the quality assessment proposed by Jadad et al.
14
Data synthesis and analysis
The common unit of measurement across all studies
was the mean change (standard error) in the level of
each biomarker after alcohol consumption compared
with the no alcohol control. This was calculated as
(meanconcentrationofbiomarkerduringalcoholcon-
sumption)−(mean concentration of biomarker during
no alcohol consumption). To determine the standard
errorofthemeanchange,weusedthecalculation:stan-
dard error mean change=square root[(standard
deviationno alcohol
2/sample sizeno alcohol)+(standard
deviationalcohol
2/sample sizealcohol)]. Not all studies
included in the systematic review reported results in
this manner. We converted error measurements
reported as standard errors to standard deviations
using the formula standard deviation=(standard
error)×square root (sample size).
15 For studies that did
not report mean concentrations of biomarkers either
before or after the intervention or that reported results
in graphical format only, we contacted the study
authors to obtain data suitable for inclusion in our
study.Inallcasestheauthorsfailedtosupplytheneces-
sary data to determine the mean change in biomarker
level, and we therefore excluded these studies from
meta-analyses.
When at least two studies reportedthe mean change
in level of a specific biomarker we carried out meta-
analyses of the effect of alcohol consumption on bio-
marker concentrations. All analyses were done using
Stata10.0.Toassessheterogeneityofthemeanchange
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Fig 2 | Forest plot of meta-analysis (random effects) of effect of alcohol consumption on levels of high and low density lipoprotein cholesterol
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lated the Q statistic (significance level P≤0.10) and the
I
2 statistic.
1617 This criterion was used to determine
whether to use a fixed or random effects model to
pool studies. Where appropriate we pooled data
according to the dose of alcohol consumed: 12.5-
29.9 g/day (about 1-2.5 drinks), 30-60 g/day (about
2.5-5 drinks), and >60 g/day (≥5 drinks). To visually
assess the mean change estimates and corresponding
95% confidence intervals across studies, we generated
forest plots and grouped studies by dose of alcohol.
We carried out sensitivity analyses based on study
quality for levels of high density lipoprotein choles-
terol, low density lipoprotein cholesterol, total choles-
terol, triglycerides, and fibrinogen. For these
biomarkers we pooled the results from crossover stu-
dies separately from before and after studies. We also
pooledresultsforthesebiomarkersstratifiedbybever-
age type (wine, beer, spirits). Data were pooled by the
methods described previously.
Finally, we used the Begg test and visual inspection
of funnel plots to assess for evidence of publication
bias.
1819 We limited this analysis to biomarkers where
a statistically significant effect of alcohol was observed
and five or more studies were meta-analysed.
RESULTS
Theliteraturesearchidentified4690articlespertaining
to the relevant exposure, outcomes, and study designs
(fig 1). Two additional articles were added from the
bibliographic search. No additional articles were sug-
gested by the content expert (KJM). After the final
review, 63 articles were deemed eligible for analysis.
Selected studies examined the effect of alcohol con-
sumption on: lipid biomarkers (47 studies), inflamma-
torymarkers(13),haemostaticfactors(14),endothelial
factors (3), and adipocyte hormones (8). Many of the
studies examined several of the biomarkers (fig 1).
Table 1 outlines the characteristics of the 63
included studies, totalling 1686 participants (1049
men and 625 women; one study of 12 participants
did not indicate sex).
20-82 Thirty six of the 63 (57%)
studies included only men, eight (12.7%) included
only women, and 19 (30%) included both. Thirty six
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Fig 3 | Forest plot of meta-analysis (fixed effects) of effect of alcohol consumption on levels of total cholesterol and triglycerides
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and after design, whereas three were parallel arm con-
trolled trials. The control beverage was generally
water, fruit juice, or a de-alcoholised drink (wine or
beer), and most studies included a washout period of
noalcoholusethatwasofsimilardurationtotheperiod
of alcohol intervention. Several studies included parti-
cipants whose clinical characteristics may have influ-
enced some of the biomarkers (for example, patients
with diabetes, smokers, or those who were overweight
orobese).Twentyeight(44%)studiescontrolledforan
increase in caloric intake from alcohol consumption
with isocaloric or controlled diets, whereas others
maintained their usual diet. Six studies included peo-
ple who were overweight or obese and three studies
specifically examined inactive people compared with
regular runners.
Meta-analyses
Of the 63 studies, 44 reported adequate data to permit
pooled analyses (see web extra figure). Most com-
monly, studies could not be included because they
did not report data in a format that permitted pooling
(for example, graphically or as percentage change), or
didnot report error calculations.Thesubsets of identi-
fiedstudieswithadequatedatadealtwithlevelsofhigh
density lipoprotein cholesterol (33 of 44), total choles-
terol (26 of 32), triglycerides (31 of 39), low density
lipoprotein cholesterol (24 of 28), apolipoprotein A1
(16 of22), Lp(a) lipoprotein (3 of5), Creactive protein
(5 of 8), interleukin 6 (2 of 4), tumour necrosis factor α
(3 of 7), plasminogen activator inhibitor 1 (3 of 3), tis-
sue plasminogen activator (3 of 4), fibrinogen (7 of 8),
and adiponectin (4 of 7; see web extra figure). See web
extra appendix 2 for details about exclusion of studies
from meta-analysis.
Lipid biomarkers
The pooled analysis of the effect of alcohol consump-
tion on mean high density lipoprotein cholesterol
showed a consistent increase in these levels but with
significant heterogeneity among studies (fig 2 and
table 2; P=0.005). Pooling of studies stratified by
dosemaypartiallyexplainthisheterogeneity.Asignif-
icant dose-response was observed between alcohol
consumption and high density lipoprotein cholesterol
levels (fig 2): 12.5-29.9 g/day (1-2 drinks, n=7), mean
difference of 0.072 mmol/L (95% confidence interval:
0.024 to 0.119); 30-60 g/day (2-4 drinks, n=24), mean
difference of 0.103 mmol/L (0.065 to 0.141); and
>60 g/day (≥5 drinks, n=2), mean difference of
0.141mmol/L(0.042to0.240;Pfortrend0.013).Simi-
lar to the effect with high density lipoprotein choles-
terol, apolipoprotein A1 also significantly increased
in a randomeffects modelpooling 16 studies(table 2).
In contrast, alcohol consumption did not signifi-
cantly change levels of total cholesterol, low density
lipoproteincholesterol,triglycerides,or Lp(a)lipopro-
tein (table 2). The 24 studies reporting on low density
lipoprotein cholesterol were pooled using a random
effects model because heterogeneity was present.
Pooled analyses stratified by dose of alcohol also
showed no significant effects of alcohol on low density
lipoprotein cholesterol. Pooled analysis of the impact
ofalcoholbydoseontriglyceridesshowedasignificant
increase at the highest dose of alcohol (>60 g/day) in
the two studies reporting alcohol consumption at this
dose: mean difference 0.274 mmol/L (0.043 to 0.505),
test for heterogeneity P=0.763 (fig 3).
Inflammatory markers
TheassociationofalcoholwithlevelsofCreactivepro-
tein, interleukin 6, and tumour necrosis factor α was
not significant (table 2). Only one study reported that
alcohol (in this case beer) increased leucocyte levels in
women (0.51 (SD 0.47)×10
9/L) but not in men (0.19
(SD 0.31)×10
9/L).
63
Haemostatic factors
Fibrinogen levels significantly decreased after alcohol
consumption (fig 4 and table 2). Meta-analyses of the
remaining haemostatic biomarkers, however, did not
show any significant effect of alcohol, including plas-
minogen activator inhibitor 1 and tissue plasminogen
activator antigens (table 2).
Data were insufficient to permit meta-analysis for
plasminogen, thromboxane, von Willebrand factor,
and e-selectin levels. One study reported a significant
increase in plasminogen levels after red wine con-
sumption in 12 men.
60 Another study reported a
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Fig 4 | Forest plot of meta-analysis of effect of alcohol consumption on levels of fibrinogen and adiponectin
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page 10 of 15 BMJ | ONLINE FIRST | bmj.comsignificant decrease in thromboxane levels after both
white and red wine consumption.
59 The two studies
reporting on the effect of alcohol on von Willebrand
factor found no significant change in these biomarker
levels.
5456 For e-selectin, one study found a significant
increaseafter alcohol consumption,
81 whereasanother
study found no change.
38
Endothelial factors
Three studies reported on the impact of alcohol on
intracellular adhesion molecule 1 and two reported
on vascular cellular adhesion molecule levels. How-
ever,only one studyreporteddata suitablefor pooling
for each biomarker. Two studies showed no impact of
alcohol on intracellular adhesion molecule,
3781
whereas one showed a significant decrease in intra-
cellular adhesion molecule 1 after consumption of
red wine but not after gin.
38 One study reported no
change in vascular cellular adhesion molecule after
alcohol consumption,
37 whereas another found a sig-
nificant decrease after consumption of red wine but
not after gin.
38
Adipocyte hormones
Adiponectin levels were consistently significantly
increased after alcohol consumption (fig 4). Only two
studies reported on the effect of alcohol on levels of
leptin;onestudyfoundasignificantincreaseafteralco-
hol consumption
64 and the other no effect.
37
Sensitivity analyses
Study quality
Study quality was analysed using the component
approach,
13 focusing primarily on study design as the
most important quality factor. Sensitivity analyses
were stratified by the two major study designs in
selected studies (24 crossover studies, 18 before and
after studies), with crossover studies being considered
the more robust study design. The findings of these
stratifiedsensitivityanalysesareinwebextraappendix
3 and show generally similar results for both types of
study design from analyses that include a sufficient
number of studies to yield stable pooled estimates—
that is, high density lipoprotein cholesterol, low den-
sity lipoprotein cholesterol, triglycerides, and fibrino-
gen. This sensitivity analysis suggests that, regardless
of the study design, alcohol had consistent effects on
biomarker levels.
See web extra appendix 4 for additional study qual-
ity characteristics. Of the 44 studies meta-analysed, 17
randomised the participants into treatment groups but
only one study described the randomisation process.
Forty three of the 44 studies described the presence
of relevant covariates, such as diet, smoking, and phy-
sical activity. Twenty of the studies measured compli-
ance with alcohol consumption, whereas 24 described
losses to attrition.
Beverage type
Analyses were also stratified by beverage type (wine,
beer, spirits). The results were similar to the combined
analyses of all beverage types (see web extra appendix
3).
Publication bias
Evidenceofpublicationbiaswasassessedforhighden-
sity lipoprotein cholesterol, apolipoprotein A1, and
fibrinogen.Noasymmetrywasfoundonvisualinspec-
tion of the funnel plot for each biomarker, suggesting
that significant publication bias was unlikely. This was
further confirmed by a non-significant Begg test for
eachoutcomeofinterest(highdensitylipoproteincho-
lesterol P=0.12, apolipoprotein A1 P=0.064, and fibri-
nogen P=0.88).
DISCUSSION
This meta-analysis shows that moderate consumption
of alcohol (up to one drink or 15 g alcohol a day for
women and up to two drinks or 30 g alcohol a day for
men) has beneficial effects on a variety of biomarkers
linkedtotheriskofcoronaryheartdisease.Theexperi-
mental interventional studies showed that alcohol
Table 2 |Summary of pooled mean difference in biomarker level after alcohol use
Biomarker
No of pooled
studies
No of pooled
participants Type of model
Pooled mean difference in
biomarker level (95% CI)
High density lipoprotein cholesterol (mmol/L) 33 796 Random 0.094 (0.064 to 0.123)*†
Low density lipoprotein cholesterol (mmol/L) 24 513 Random −0.11 (−0.22 to 0.006)†
Total cholesterol (mmol/L) 26 596 Fixed 0.00 (−0.066 to 0.067)
Triglycerides (mmol/L) 31 752 Fixed 0.016 (−0.018 to 0.051)
Apolipoprotein A1 (g/L) 16 374 Random 0.101 (0.073 to 0.129)*†
Lp(a) lipoprotein (mg/dL) 3 114 Fixed 0.80 (−4.17 to 5.76)
C reactive protein (mg/L) 5 186 Fixed −0.11 (−0.31 to 0.10)
Interleukin 6 (pg/mL) 2 144 Fixed 0.502 (−3.482 to 4.486)
Tumour necrosis factor α (pg/mL) 3 121 Fixed −0.469 (−32.02 to 31.08)
Plasminogen activator inhibitor 1 (ng/mL) 3 67 Fixed 3.285 (−0.898 to 7.469)
Tissue plasminogen activator (ng/mL) 3 67 Fixed 0.754 (−0.132 to 1.641)
Fibrinogen (g/L) 7 387 Fixed −0.20 (−0.29 to −0.11)*
Adiponectin (mg/L) 4 108 Fixed 0.56 (0.39 to 0.72)*
*Indicates significant (P<0.01) change in biomarker level after alcohol use compared with a period of no alcohol use.
†Heterogeneity detected across pooled studies, where Q statistic P<0.10.
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ofhighdensitylipoproteincholesterol,apolipoprotein
A1, and adiponectin and significantly decreased fibri-
nogen levels, all changes reported to be cardio
protective.
4-8
Comparison with other studies
The findings from our review expand on those
reported a decade ago by Rimm et al,
3 which focused
only on alcohol’s effect on lipids and haemostatic fac-
tors.Sincethat reviewsubstantialgrowthhas occurred
in research on the effect of alcohol on the more tradi-
tional biomarkers associated with cardiovascular risk
as well as on newer biomarkers such as inflammatory
markers,endothelialfactors,andadipocytehormones.
To identify eligible studies we followed a similar pro-
tocol to that used by the previous reviewers, but we
also required that eligible studies had to compare fast-
ing levels of biomarkers after alcohol consumption
with those from a period of no alcohol use.
Similar to the review by Rimm et al, our updated
meta-analyses found increases in levels of high density
lipoprotein cholesterol and apolipoprotein A1. For
30 g alcohol consumed a day (about two drinks)
Rimm et al reported an increase in high density lipo-
protein cholesterol level of 3.99 mg/dL (0.103 mmol/
L) (95% confidence interval 3.25 to 4.73) and an
increase in apolipoprotein A1 of 8.82 mg/dL (7.79 to
9.86). For a similar dose of alcohol (30 g a day was the
standard dose used by Rimm et al), our results are
nearlythesame:anincreaseinhighdensitylipoprotein
cholesterollevelof3.66mg/dL(95%confidenceinter-
val: 2.22 to 5.13) and an increasein apolipoprotein A1
of 8.67 mg/dL (6.81 to 10.32). In contrast with the
study by Rimm et al, however, we observed that alco-
hol consumption significantly decreased fibrinogen
concentrations. Evidence that alcohol decreases fibri-
nogen levels from experimental studies supports an
important postulated mechanism by which alcohol
consumptionprotectsagainstcertainaspectsofcardio-
vascular disease, such as coronary heart disease.
383
Another finding that varied from the earlier review
was that alcohol consumption did not increase trigly-
ceridelevelsasidefrompooledresultsfromtwostudies
of heavy alcohol consumption (>60 g/day, or >4
drinks a day). Although the results of the two studies
should be viewed cautiously as they pool two different
studydesigns(acrossoverstudy
32andabeforeandafter
study
34), they do indicate an adverse effect of heavy
alcohol consumption on triglyceride levels. At low
levelsofalcoholconsumption,ourfindingsdonotsup-
port the previously reported association of alcohol
consumption and raised triglyceride levels. Further-
more, we also determined that different types of alco-
holic beverage (wine, beer, and spirits) have similar
effects on biomarkers. Inferences on beverage type
should be viewed with some caution, however, as
most of the studies used wine as the alcohol inter-
vention. This preference for using wine, and in most
cases red wine, as the type of alcohol for intervention
may be related to the other chemical components of
red wine, such as polyphenols, which are believed to
have cardioprotective effects.
3038424550 However, it is
interesting that in many of these studies, comparisons
were made either with a non-red wine alcohol inter-
ventionorwithde-alcoholisedredwineanditwascon-
cluded that the effect observed was most likely due to
alcohol rather than to the other components in red
wine.
304245
This review also examined results for several other
biomarkers that had not previously been evaluated,
mostnotablyadiponectin,anabundantadipocytehor-
mone that has been associated with lower risk of both
diabetes
84andcoronaryheartdisease.
85Inpooledana-
lyses, adiponectin levels were significantly increased
by alcohol intake. Taken together, these findings
extendpreviousevidence supportinganapparentcau-
sal role for alcohol consumption in preventing coron-
aryheartdiseasethroughfavourableeffectsonlevelsof
high density lipoprotein cholesterol, fibrinogen, and
adiponectin and limited adverse effects on triglycer-
ides at levels of alcohol consumption that are consid-
ered “not risky.”
Potential biological mechanisms and clinical context
Our results thus implicate reverse cholesterol trans-
port, haemostasis, and insulin sensitivity in the path-
way by which alcohol consumption might prevent
cardiovascular disease. The mechanisms by which
alcohol influences high density lipoprotein choles-
terol, fibrinogen, and adiponectin are not fully under-
stood. In the case of high density lipoprotein
cholesterol, various mechanisms have been proposed,
including an increased transport rate of lipoproteins
36
andincreasedlipoproteinlipaseactivity.
5886Theeffect
on fibrinogen is also not well understood, although
alcoholseemstoinfluencetheconformationandstabi-
lity of fibrinogen molecules.
87 For adiponectin, one
study showed that alcohol consumption increases
expression of the ADIPOQ gene in adipose tissue,
but little else is known about this effect.
51
Our findings need to be put into a clinical context.
The significant changes in levels of high density lipo-
protein cholesterol, fibrinogen, and adiponectin after
alcohol consumption were well within a pharmacolo-
gically relevant magnitude. In our systematic review,
we determined that alcohol consumption increased
high density lipoprotein cholesterol levels by about
0.1 mmol/L overall and in a dose-response manner
(0.072 mmol/L for 1-2 drinks a day, 0.10 mmol/L for
2-4drinksaday,and0.14mmol/Lfor≥4drinksaday).
This degree of increase is greater than any currently
available single pharmacological therapy, including
fibrates (approved by the Food and Drug Administra-
tion for people with low levels of high density lipopro-
tein cholesterol). For example, a systematic review of
fibrates on high density lipoprotein cholesterol levels
showed an overall increase of 2.6 mg/dL
88 compared
with our findings of alcohol increasing high density
lipoprotein cholesterol levels by 3.5-4 mg/dL. Simi-
larly,alcoholconsumptiondecreasedfibrinogenlevels
by 0.20 g/L. Given that an increase of 1 g/L has been
RESEARCH
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coronary heart disease in pooled cohort studies,
89 this
magnitude of decrease in fibrinogen could account for
a substantial decrease in heart disease among
drinkers.
90 The clinical implications of alcohol’s effect
on adiponectin is less certain since this biomarker is
less commonly examined in the clinical setting. An
increase of about 0.6 mg/L represents approximately
1 standard deviation in adiponectin levels in the col-
lected trials, or similar to the effect of thiazolinediones
on this insulin sensitising adipokine.
91
Limitations of the study
Our review has some limitations and caveats. We did
not formally search the grey literature, but we are con-
fident that our search of the peer reviewed literature
captured all relevant articles. The studies that we
pooled did lack uniformity. Duration and dosing of
the alcohol interventions were, however, different, as
werethecharacteristicsoftheparticipants.Thereforeit
ispossiblethatpotentialconfounderssuchassmoking,
physical inactivity, body weight, and diet could have
affected our findings.
92 Also, none of the studies
blinded participants to alcohol consumption. How-
ever, owing to the taste and physiological effects of
alcohol, it may not be possible to blind participants to
this intervention. We chose to evaluate stable circulat-
ing cellular and molecular biomarkers associated with
cardiovascular disease, in particular atherothrombotic
and coronary heart disease. More variable measures,
suchasbloodpressure,canbeinfluencedbyalcoholin
complex,biphasicdirectionsafteringestionandhence
are less amenable to being summarised. Our selection
of biomarkers for study was guided by links to cardio-
vascular pathophysiology. Other biomarkers may be
of relevance to alcohol’s effects on other health condi-
tions—for example, cancer.
12 Lastly, although we
found that alcohol consumption has favourable effects
on some of the biomarkers associated with coronary
heart disease, this remains indirect evidence for the
mechanisms by which alcohol may cause cardio-
protection.
Conclusions and policy implications
This systematic review provides a thorough examina-
tion of the literature on the effect of alcohol
consumption on biomarkers associated with cardio-
vascular disease, and produces compelling, indirect
evidenceinsupportofacausalprotectiveeffectofalco-
hol. Our companion systematic review assessing alco-
hol associations withclinically relevantcardiovascular
end points offers parallel evidence of the protective
effect of alcohol consumption.
93 These combined
reviews provide a foundation of knowledge on which
clinical and public health messaging can be discussed.
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